Literature DB >> 1320517

Reversible mental deterioration and neurological disturbances with o,p'-DDD therapy.

E Bollen1, J B Lanser.   

Abstract

A patient with serious neurological and neuropsychological side-effects of a 2-year treatment with 1,1-dichloro-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p'-DDD) for adrenal carcinoma showed complete recovery after discontinuation of the drug. Studying a larger number of patients during and after long term treatment with o,p'-DDD is indicated. If results of this report are confirmed, therapy should not be discontinued even if serious side effects occur.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1320517     DOI： 10.1016/0303-8467(92)90020-4

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN： 0303-8467            Impact factor:   1.876


  5 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Long QT syndrome under mitotane therapy.

Authors:  R U Pliquett; U Eichfeld; M Stumvoll; C A Koch
Journal:  J Endocrinol Invest       Date:  2007-02       Impact factor: 4.256

3.  Case Report: Adjuvant Therapy with a High Dose of Mitotane for Adrenocortical Carcinoma in a 4-year-old Boy.

Authors:  Takako Goto; Kenichi Miyako; Ryuichi Kuromaru; Kenji Ihara; Hiroyuki Torisu; Masafumi Sanefuji; Rie Nagamatsu; Toshiro Hara
Journal:  Clin Pediatr Endocrinol       Date:  2008-08-08

Review 4.  Health-Related Quality of Life in Adrenocortical Carcinoma.

Authors:  Rebecca V Steenaard; Laura A Michon; Harm R Haak
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639

Review 5.  EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.

Authors:  Rebecca V Steenaard; Marieke Rutjens; Madeleine H T Ettaieb; Max M van Noesel; Harm R Haak
Journal:  Discov Oncol       Date:  2022-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.